Anecdotally, Bunce is already seeing the impact of GLP-1 agonist medications on his patients
Orally Gastrointestinal discomfort, allergic reactions, worsening of asthma, toxicity, and interference with other medications
These updates are not the same as full peer-reviewed publications, so treat them as preliminary until complete data are published
Current guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity (IFSO) support consideration in patients with BMI 35 kg/m regardless of comorbidities, or BMI 30-34.9 kg/m with metabolic disease
[1] Metformin similarly causes gastrointestinal symptoms, with diarrhea, nausea, and abdominal cramping affecting 10-25% of users, especially when initiating therapy